Berberine-loaded targeted nanoparticles as specific Helicobacter pylori eradication therapy: In vitro and in vivo study

Nanomedicine

Volumn 10, Issue 1, 2015, Pages 57-71

  Lin, Yu Hsin ^a   Lin, Jui Hsiang ^b   Chou, Shen Chieh ^a   Chang, Shu Jen ^a   Chung, Chun Chia ^a   Chen, Yueh Sheng ^a   Chang, Chiung Hung ^a,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b Bio medical Carbon Technology Co Ltd   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

berberine; fucose conjugated nanoparticle; gastric inflammation; Helicobacter pylori; heparin

Indexed keywords

BERBERINE; CHITOSAN; FUCOSE; HEPARIN; NANOPARTICLE; TREHALOSE;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIUM COLONY; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ERADICATION THERAPY; FREEZE DRYING; GROWTH INHIBITION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PH; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STATIC ELECTRICITY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECTS; HELICOBACTER INFECTIONS; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY;

ANIMALS; BERBERINE; CHITOSAN; DRUG DELIVERY SYSTEMS; FUCOSE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HEPARIN; HUMANS; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES;

EID: 84921522655     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.76     Document Type: Article

References (53)

1. Beil W, Kilian P. EPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells. Phytomedicine 14(6), 5-8 (2007).
2. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 96(2), 615-625 (1989).
3. Hazell SL, Lee A, Brady L, Hennessy W. Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium. J. Infect. Dis. 153(4), 658-663 (1986).
4. Fedwick JP, Lapointe TK, Meddings JB, Sherman PM, Buret AG. Helicobacter pylori activates myosin light-chain kinase to disrupt claudin-4 and claudin-5 and increase epithelial permeability. Infect. Immun. 73(12), 7844-7852 (2005).
5. Falk P, Roth KA, Borén T, Westblom TU, Gordon JI, Normark S. An in vitro adherence assay reveals that Helicobacter pylori exhibits cell lineage-specific tropism in the human gastric epithelium. Proc. Natl Acad. Sci. USA 90(5), 2035-2039 (1993).
6. Lin YH, Tsai SC, Lai CH, Lee CH, He ZS, Tseng GC. Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori. Biomaterials 34(18), 4466-4479 (2013).
7. Özden A, Seven G, BektaM. Effectiveness of different treatment regimens in Helicobacter pylori eradication: ten-year experience of a single institution. Turk. J. Gastroenterol. 21(3), 218-223 (2010).
8. Rangari VK, Mohammad GM, Jeelani S et al. Synthesis of Ag/CNT hybrid nanoparticles and fabrication of their nylon-6 polymer nanocomposite fibers for antimicrobial applications. Nanotechnology 21(9), 095102 (2010).
9. Guo CY, Wu YB, Liu HL, Wu JY, Zhong MZ. Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. World J. Gastroenterol. 10(5), 747-749 (2004).
10. Koletzko S, Richy F, Bontems P et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 55(12), 1711-1716 (2006).
11. de Bortoli N, Leonardi G, Ciancia E et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am. J. Gastroenterol. 102(5), 951-956 (2007).
12. Du P, Zhu S, Lü P. Antibacterial activity of 20 kinds of Chinese medicinal materials for Helicobacter pylori in vitro. Zhong Yao Cai. 24(3), 188-189 (2001).
13. Yang P, Song DQ, Li YH et al. Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators. Bioorg. Med. Chem. Lett. 18(16), 4675-4677 (2008).
14. Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J. Ethnopharmacol. 126(1), 5-17 (2009).
15. Amin AH, Subbaiah TV, Abbasi KM. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can. J. Microbiol. 15(9), 1067-1076 (1969).
16. Chung JG, Wu LT, Chang SH, Lo HH, Hsieh SE. Inhibitory actions of berberine on growth and arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Int. J. Toxicol. 18(1), 35-40 (1999).
17. Mahady GB, Pendland SL, Stoia A, Chadwick LR. In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis. Phytother. Res. 17(3), 217-221 (2003).
18. Wang YX, Zheng YM. Ionic mechanism responsible for prolongation of cardiac action-potential duration by berberine. J. Cardiovasc. Pharmacol. 30(2), 214-222 (1997).
19. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55(3), 329-347 (2003).
20. Khan MK, Minc LD, Nigavekar SS et al. Fabrication of {198Au0} radioactive composite nanodevices and their use for nanobrachytherapy. Nanomedicine 4(1), 57-69 (2008).
21. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2(2), 53-65 (2006).
22. Chang CH, Huang WY, Lai CH et al. Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori. Acta Biomater. 7(2), 593-603 (2011).
23. Becker DJ, Lowe JB. Fucose: biosynthesis and biological function in mammals. Glycobiology 13(7), 41R-53R (2003).
24. Mitchell E, Houles C, Sudakevitz D et al. Structural basis for oligosaccharide-mediated adhesion of Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. Nat. Struct. Biol. 9(12), 918-921 (2002).
25. Loris R, Tielker D, Jaeger KE, Wyns L. Structural basis of carbohydrate recognition by the lectin LecB from Pseudomonas aeruginosa. J. Mol. Biol. 331(4), 861-870 (2003).
26. Thanou M, Verhoef JC, Junginger HE. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 50(1), S91-S101 (2001).
27. Mansouri S, Cuie Y, Winnik F et al. Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 27(9), 2060-2065 (2006).
28. Sameti M, Bohr G, Ravi Kumar MN et al. Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery. Int. J. Pharm. 266(1-2), 51-60 (2003).
29. Elbein AD, Pan YT, Pastuszak I, Carroll D. New insights on trehalose: a multifunctional molecule. Glycobiology 13(4), 17R-27R (2003).
30. Sashiwa H, Aiba S. Chemically modified chitin and chitosan as biomaterials. Prog. Polym. Sci. 29(9), 887-908 (2004).
31. Donati I, Stredanska S, Silvestrini G et al. The aggregation of pig articular chondrocyte and synthesis of extracellular matrix by a lactose-modified chitosan. Biomaterials 26(9), 987-998 (2005).
32. Wang SD, Song BS, Li K. Determination of berberine in decocted liquid from shenshu granules with water by reversed-phase liquid chromatography. Se Pu. 18(3), 261-262 (2000).
33. Richards CL, Buchholz BJ, Ford TE, Broadaway SC, Pyle BH, Camper AK. Optimizing the growth of stressed Helicobacter pylori. J. Microbiol. Methods 84(2), 174-182 (2011).
34. Lin YH, Lin JH, Peng SF et al. Multifunctional gentamicin supplementation of poly (glutamic acid)-based hydrogels for wound dressing application. J. Appl. Polym. Sci. 120(2), 1057-1068 (2011).
35. Huang WY, Yeh CL, Lin JH, Yang JS, Ko TH, Lin YH. Development of fibroblast culture in three-dimensional activated carbon fiber-based scaffold for wound healing. J. Mater. Sci. Mater. Med. 23(6), 1465-1478 (2012).
36. Lin YH, Chiou SF, Lai CH et al. Formulation and evaluation of water-in-oil amoxicillin-loaded nanoemulsions using for Helicobacter pylori eradication. Process Biochem. 47(10), 1469-1478 (2012).
37. Sogias IA, Williams AC, Khutoryanskiy VV. Why is chitosan mucoadhesive? Biomacromolecules 9(7), 1837-1842 (2008).
38. Ramesan RM, Sharma CP. Modification of chitosan nanoparticles for improved gene delivery. Nanomedicine (Lond). 7(1), 5-8 (2012).
39. Madrid JF, Leis O, Díaz-Flores L, Sáez FJ, Hernández F. Lectin-gold localization of fucose residues in human gastric mucosa. J. Histochem. Cytochem. 46(11), 1311-1320 (1998).
40. Moriwaki K, Miyoshi E. Fucosylation and gastrointestinal cancer. World J. Hepatol. 2(4), 151-161 (2010).
41. Kim YS, Kim YW, Siddiqui B, Tsao D. Membrane-associated, fucose-containing glycoproteins and glycolipids of cultured epithelial cells from human colonic adenocarcinoma and fetal intestine. Eur. J. Cancer Clin. Oncol. 18(12), 1329-1336 (1982).
42. Wen S, Moss SF. Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer Lett. 282(1), 1-8 (2009).
43. Wroblewski LE, Peek RM Jr, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin. Microbiol. Rev. 23(4), 713-739 (2010).
44. Khanvilkar K, Donovan MD, Flanagan DR. Drug transfer through mucus. Adv. Drug Deliv. Rev. 48(2-3), 173-193 (2001).
45. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 78(1-3), 43-48 (1992).
46. Miyazaki S, Nakayama A, Oda M, Takada M, Attwood D. Chitosan and sodium alginate based bioadhesive tablets for intraoral drug delivery. Biol. Pharm. Bull. 17(5), 745-747 (1994).
47. Amiji MM. Tetracycline-containing chitosan microspheres for local treatment of Helicobacter pylori infection. Cellulose 14(1), 3-14 (2007).
48. Yang P, Song DQ, Li YH et al. Synthesis and structure-activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators. Bioorg. Med. Chem. Lett. 18(16), 4675-4677 (2008).
49. Casu B, Gennaro U. A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr. Res. 39(1), 168-176 (1975).
50. Li Y, Wang HY, Cho CH. Association of heparin with basic fibroblast growth factor, epidermal growth factor, and constitutive nitric oxide synthase on healing of gastric ulcer in rats. J. Pharmacol. Exp. Ther. 290(2), 789-796 (1999).
51. Konturek PC, Konturek SJ, Brzozowski T, Ernst H. Epidermal growth factor and transforming growth factor-alpha: role in protection and healing of gastric mucosal lesions. Eur. J. Gastroenterol. Hepatol. 7(10), 933-937 (1995).
52. Hall AJ, Tripp M, Howell T, Darland G, Bland JS, Babish JG. Gastric mucosal cell model for estimating relative gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Prostaglandins Leukot. Essent. Fatty Acids 75(1), 9-17 (2006).
53. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci. 14(3), 201-207 (2001).